[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 11 of about 11
1. Spinelli SL, Casey AE, Pollock SJ, Gertz JM, McMillan DH, Narasipura SD, Mody NA, King MR, Maggirwar SB, Francis CW, Taubman MB, Blumberg N, Phipps RP: Platelets and megakaryocytes contain functional nuclear factor-kappaB. Arterioscler Thromb Vasc Biol; 2010 Mar;30(3):591-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the presence and role of NF-kappaB proteins in megakaryocytes and platelets.
  • As NF-kappaB inhibitors are being developed as antiinflammatory and anticancer agents, they may have unintended effects on platelets.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2004 Dec;50(12):2271-8 [15472037.001]
  • [Cites] Cell. 2005 Aug 12;122(3):379-91 [16096058.001]
  • [Cites] J Biol Chem. 2005 Nov 25;280(47):39474-84 [16195235.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6680-4 [17072321.001]
  • [Cites] Circ Res. 2007 Jan 5;100(1):27-40 [17204662.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1975-83 [17110454.001]
  • [Cites] J Biol Chem. 2007 Apr 6;282(14):10146-52 [17276989.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3284-90 [17170121.001]
  • [Cites] Blood. 2007 May 1;109(9):3679-86 [17213284.001]
  • [Cites] Blood. 2007 May 1;109(9):3741-4 [17213293.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4767-73 [17510405.001]
  • [Cites] Thromb Haemost. 2008 Jan;99(1):86-95 [18217139.001]
  • [Cites] Blood. 2008 Jul 1;112(1):90-9 [18310501.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4051-60 [18755987.001]
  • [Cites] J Cell Biol. 2001 Aug 6;154(3):485-90 [11489912.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21317-24 [11287411.001]
  • [Cites] J Thromb Haemost. 2009 Aug;7(8):1333-43 [19566544.001]
  • [Cites] J Cell Biol. 2002 Apr 15;157(2):265-75 [11940607.001]
  • [Cites] Thromb Res. 2002 May 15;106(4-5):199-203 [12297126.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):2963-8 [12433922.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2285-93 [12433680.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32861-71 [12813046.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1690-6 [12855480.001]
  • [Cites] Thromb Haemost. 2003 Oct;90(4):738-48 [14515197.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):2131-7 [14500287.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):104-12 [14691478.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5297-303 [15100268.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1361-8 [15130939.001]
  • [Cites] Eur J Biochem. 1987 Apr 1;164(1):189-95 [3830180.001]
  • [Cites] Crit Rev Oncog. 1992;3(4):401-46 [1384720.001]
  • [Cites] Genes Dev. 1992 Dec;6(12A):2352-63 [1459457.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):463-75 [9042860.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21096-103 [9261113.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5556-61 [9576921.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):12779-85 [9582304.001]
  • (PMID = 20042710.001).
  • [ISSN] 1524-4636
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / T32-DE07165; United States / NHLBI NIH HHS / HL / R21 HL086367; United States / NHLBI NIH HHS / HL / HL086367; United States / NINDS NIH HHS / NS / R01 NS054578; United States / NHLBI NIH HHS / HL / RC1 HL100051; United States / NIDCR NIH HHS / DE / DE011390; United States / NHLBI NIH HHS / HL / R01 HL078603-04; United States / NIEHS NIH HHS / ES / ES01247; United States / NHLBI NIH HHS / HL / HL095467-01A1; United States / NIEHS NIH HHS / ES / P30 ES001247; United States / NIEHS NIH HHS / ES / P30 ES001247-269015; United States / NHLBI NIH HHS / HL / R01 HL095467; United States / NHLBI NIH HHS / HL / HL095467; United States / NIDCR NIH HHS / DE / R01 DE011390; United States / NHLBI NIH HHS / HL / RC1 HL100051-01; United States / NINDS NIH HHS / NS / NS054578; United States / NHLBI NIH HHS / HL / RC1HL100051; United States / NHLBI NIH HHS / HL / HL078603-04; United States / NHLBI NIH HHS / HL / R01 HL078603; United States / NIDCR NIH HHS / DE / T32 DE007165; United States / NHLBI NIH HHS / HL / R01 HL095467-01A1; United States / NHLBI NIH HHS / HL / HL078603; United States / CCR NIH HHS / RC / HL100051-01; United States / NIEHS NIH HHS / ES / ES001247-269015; United States / NIDCR NIH HHS / DE / R01 DE011390-22; United States / NIDCR NIH HHS / DE / DE011390-22
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3-(4-methylphenylsulfonyl)-2-propenenitrile; 0 / NF-kappa B; 0 / NF-kappa B p50 Subunit; 0 / Nitriles; 0 / Sulfones; 0 / Transcription Factor RelA
  • [Other-IDs] NLM/ NIHMS172813; NLM/ PMC2853005
  •  go-up   go-down


2. Kalita K, Kharebava G, Zheng JJ, Hetman M: Role of megakaryoblastic acute leukemia-1 in ERK1/2-dependent stimulation of serum response factor-driven transcription by BDNF or increased synaptic activity. J Neurosci; 2006 Sep 27;26(39):10020-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of megakaryoblastic acute leukemia-1 in ERK1/2-dependent stimulation of serum response factor-driven transcription by BDNF or increased synaptic activity.
  • Serum response factor (SRF)-mediated transcription contributes to developmental and adult brain plasticity.
  • MKL1 expression was found in newborn rat cortical or hippocampal neurons in culture as well as in adult rat forebrain.
  • [MeSH-minor] 4-Aminopyridine / pharmacology. Amides / pharmacology. Animals. Animals, Newborn. Bicuculline / pharmacology. Butadienes / pharmacology. COS Cells. Cells, Cultured / metabolism. Cercopithecus aethiops. Cerebral Cortex / cytology. Chromones / pharmacology. Cysteine-Rich Protein 61. Genes, fos. Hippocampus / cytology. Immediate-Early Proteins / biosynthesis. Immediate-Early Proteins / genetics. Intercellular Signaling Peptides and Proteins / biosynthesis. Intercellular Signaling Peptides and Proteins / genetics. Morpholines / pharmacology. N-Methylaspartate / pharmacology. Nitriles / pharmacology. Potassium Chloride / pharmacology. Prosencephalon / cytology. Proto-Oncogene Proteins c-fos / biosynthesis. Proto-Oncogene Proteins c-jun / biosynthesis. Proto-Oncogene Proteins c-jun / genetics. Pyramidal Cells / drug effects. Pyramidal Cells / metabolism. Pyridines / pharmacology. RNA Interference. Rats. Rats, Sprague-Dawley. Signal Transduction / physiology. Transfection

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. 4-AMINOPYRIDINE .
  • Hazardous Substances Data Bank. POTASSIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005865.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS047341-01; United States / NCRR NIH HHS / RR / RR015576-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amides; 0 / Brain-Derived Neurotrophic Factor; 0 / Butadienes; 0 / Chromones; 0 / Cyr61 protein, rat; 0 / Cysteine-Rich Protein 61; 0 / Immediate-Early Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Morpholines; 0 / Nitriles; 0 / Proto-Oncogene Proteins c-fos; 0 / Proto-Oncogene Proteins c-jun; 0 / Pyridines; 0 / Serum Response Factor; 0 / Transcription Factors; 0 / U 0126; 138381-45-0 / Y 27632; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 6384-92-5 / N-Methylaspartate; 660YQ98I10 / Potassium Chloride; BH3B64OKL9 / 4-Aminopyridine; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; Y37615DVKC / Bicuculline
  •  go-up   go-down


3. Delgado-Lamas JL, Garcés-Ruiz OM, Aguilar-López LB, Borjas-Gutiérrez C, Flores-Márquez MR, Luna-Zaizar H, Delgado-Chávez R: [A clinical and therapeutic analysis in acute megakaryoblastic leukemia]. Rev Med Inst Mex Seguro Soc; 2009 Mar-Apr;47(2):193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical and therapeutic analysis in acute megakaryoblastic leukemia].
  • [Transliterated title] Análisis clínico-terapéutico de leucemia aguda megacarioblástica.
  • OBJECTIVE: to show clinical and therapeutic findings in patients with diagnosis of acute megakaryoblastic leukemia (AML).
  • RESULTS: Fourteen were women, the median age was 43 years, 18 were treated with antineoplasic agents, ten obtained response, six complete and four partial.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / diagnosis. Leukemia, Megakaryoblastic, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744390.001).
  • [ISSN] 0443-5117
  • [Journal-full-title] Revista médica del Instituto Mexicano del Seguro Social
  • [ISO-abbreviation] Rev Med Inst Mex Seguro Soc
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


Advertisement
4. Corm S, Renneville A, Rad-Quesnel E, Grardel N, Preudhomme C, Quesnel B: Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. Leukemia; 2007 Nov;21(11):2376-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation.
  • [MeSH-major] Drug Resistance, Neoplasm. Fusion Proteins, bcr-abl / genetics. Fusion Proteins, bcr-abl / physiology. Leukemia, Megakaryoblastic, Acute / drug therapy. Leukemia, Megakaryoblastic, Acute / genetics. Piperazines / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Adult. Aged. Benzamides. Dasatinib. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Imatinib Mesylate. Male. Middle Aged. Recombinant Fusion Proteins / chemistry. Thiazoles / therapeutic use. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17554376.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Recombinant Fusion Proteins; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  •  go-up   go-down


5. Hirose Y, Kiyoi H, Iwai M, Yokozawa T, Ito M, Naoe T: Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis. Int J Hematol; 2002 Nov;76(4):349-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis.
  • The prognosis of patients with chronic myeloid leukemia in blastic crisis (CML-BC) remains extremely poor, and multiagent chemotherapy regimens commonly used to treat acute leukemia offer only short-term benefits.
  • Therefore, the advent of the novel molecularly targeted anticancer agent imatinib mesylate is a breakthrough in CML therapy.
  • We present a CML patient in megakaryoblastic crisis with severe myelofibrosis, who was treated with imatinib at a dosage of 400 mg/day and achieved complete remission together with a marked regression of myelofibrosis after 1 month.
  • The effect of imatinib on the long-term prognosis remains unclear, although the agent is clearly a promising drug for treating CML-BC even in cases of myelofibrosis.
  • [MeSH-major] Blast Crisis / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / administration & dosage. Primary Myelofibrosis / drug therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Benzamides. Bone Marrow / pathology. Female. Humans. Imatinib Mesylate. Megakaryocytes / pathology

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hematol. 2001 Apr;73(3):278-91 [11345193.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 20;91(2):163-8 [9923858.001]
  • [Cites] Blood. 2000 Aug 1;96(3):925-32 [10910906.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3343-56 [11071626.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1201-7 [1873771.001]
  • [Cites] Blood. 2002 May 15;99(10):3547-53 [11986206.001]
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1330-40 [10219069.001]
  • [Cites] Br J Haematol. 2000 Jan;108(1):64-71 [10651725.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):2994-3009 [11408494.001]
  • [Cites] Blood. 2002 May 15;99(10):3854-6 [11986248.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2558-62 [7708684.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Semin Hematol. 2001 Jul;38(3 Suppl 8):9-14 [11526596.001]
  • [Cites] Br J Haematol. 2000 Jul;110(1):2-11 [10930974.001]
  • [Cites] J Clin Invest. 2000 Jan;105(1):3-7 [10619854.001]
  • [Cites] Ann Hematol. 2001 Sep;80(9):516-20 [11669299.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2632-41 [10594858.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] N Engl J Med. 1999 Jul 15;341(3):164-72 [10403855.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3691-8 [9345054.001]
  • [Cites] Blood Cells Mol Dis. 1997 Dec;23(3):380-94 [9446752.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4947-52 [9389713.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] Lancet. 2002 Feb 9;359(9305):487-91 [11853795.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2246-53 [10979973.001]
  • [Cites] Blood. 2002 Jan 1;99(1):381-3 [11756197.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] Am J Clin Pathol. 1971 Jul;56(1):24-31 [5556211.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3195-9 [11050003.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1616-20 [9362160.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Blood. 2002 May 15;99(10):3530-9 [11986204.001]
  • [Cites] Lancet. 2002 Feb 9;359(9305):481-6 [11853794.001]
  • [Cites] Thromb Haemost. 1997 Aug;78(2):892-6 [9268191.001]
  • (PMID = 12463599.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


6. Fadilah SA, Raja-Zahratul-Azma RS, Leong CF: Extensive myelofibrosis responsive to treatment for acute erythroblastic leukaemia. Malays J Pathol; 2006 Jun;28(1):55-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive myelofibrosis responsive to treatment for acute erythroblastic leukaemia.
  • Intense myelofibrosis is rarely associated with de novo acute myeloid leukaemia (AML) except in acute megakaryoblastic leukaemia (AML-M7) where there is diffuse marrow fibrosis as a consequence of proliferation of neoplastic myeloid cells.
  • AML associated with significant myelofibrosis developing both de novo or secondary to primary (idiopathic) myelofibrosis is characterised by a fulminant course and extremely poor prognosis, primarily due to treatment-resistant disease.
  • The prognostic value of degree of marrow fibrosis in de novo AML has been poorly investigated.
  • We describe a case of extensive myelofibrosis associated with acute erythroblastic leukaemia (AML-M6) that responded to induction therapy of the leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Erythroblastic, Acute / complications. Leukemia, Erythroblastic, Acute / drug therapy. Primary Myelofibrosis / complications. Primary Myelofibrosis / drug therapy
  • [MeSH-minor] Adult. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Female. Humans. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / pathology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694960.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


7. Wang D, Ke XY, Wang J, Xu F, Hu YF: [Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia]. Zhonghua Yi Xue Za Zhi; 2007 May 29;87(20):1384-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia].
  • OBJECTIVE: To assess the correlation of the multidrug resistance-1 (MDR1) gene single nucleotide polymorphisms (SNP) C1236T, G2677T/A and C3435T with the outcome of induction chemotherapy in patients with de novo acute myeloid leukemia (AML).
  • [MeSH-major] Leukemia, Myeloid / genetics. P-Glycoprotein / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Base Sequence. DNA Mutational Analysis. Female. Gene Frequency. Genotype. Humans. Leukemia, Erythroblastic, Acute / drug therapy. Leukemia, Erythroblastic, Acute / genetics. Leukemia, Erythroblastic, Acute / pathology. Leukemia, Megakaryoblastic, Acute / drug therapy. Leukemia, Megakaryoblastic, Acute / genetics. Leukemia, Megakaryoblastic, Acute / pathology. Leukemia, Monocytic, Acute / drug therapy. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / pathology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Leukemia, Myelomonocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Myelomonocytic, Acute / pathology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / pathology. Male. Middle Aged. P-Glycoproteins. Prognosis. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785057.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / P-Glycoprotein; 0 / P-Glycoproteins
  •  go-up   go-down


8. Fouillard L, Labopin M, Meloni G, Polge E, Gorin NC, Frassoni F: Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia. Haematologica; 2004 Jan;89(1):107-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
  • [MeSH-major] Amsacrine / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / therapeutic use. Cytarabine / therapeutic use. Etoposide / therapeutic use. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Busulfan / therapeutic use. Combined Modality Therapy / methods. Cyclophosphamide / therapeutic use. Drug Combinations. Female. Humans. Leukemia, Erythroblastic, Acute / drug therapy. Leukemia, Erythroblastic, Acute / therapy. Leukemia, Megakaryoblastic, Acute / drug therapy. Leukemia, Megakaryoblastic, Acute / therapy. Leukemia, Monocytic, Acute / drug therapy. Leukemia, Monocytic, Acute / therapy. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / therapy. Leukemia, Myelomonocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / therapy. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / therapy. Male. Middle Aged. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14754615.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Letter; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Drug Combinations; 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan; U68WG3173Y / Carmustine; BAVC protocol
  •  go-up   go-down


9. Lane WJ, Dias S, Hattori K, Heissig B, Choy M, Rabbany SY, Wood J, Moore MA, Rafii S: Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood; 2000 Dec 15;96(13):4152-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, it is demonstrated that SDF-1 induces the expression and release of gelatinase B (MMP-9) by purified mature polyploid human MKs and an adeno-CXCR4-infected megakaryocytic cell line.
  • [MeSH-major] Blood Platelets / cytology. Chemokines, CXC / physiology. Chemotactic Factors / pharmacology. Chemotaxis / drug effects. Extracellular Matrix Proteins / physiology. Hydroxamic Acids. Megakaryocytes / drug effects. Metalloendopeptidases / physiology. Pyrazines
  • [MeSH-minor] Adult. Animals. Cells, Cultured / drug effects. Chemokine CXCL12. Culture Media, Serum-Free. Enzyme Induction / drug effects. Humans. Leukemia, Megakaryoblastic, Acute / pathology. Matrix Metalloproteinase 9 / biosynthesis. Matrix Metalloproteinase 9 / secretion. Matrix Metalloproteinase Inhibitors. Mice. Mice, Inbred BALB C. Protease Inhibitors / pharmacology. Receptors, CXCR4 / biosynthesis. Receptors, CXCR4 / genetics. Receptors, CXCR4 / physiology. Recombinant Fusion Proteins / physiology. Sulfonamides. Thrombin / pharmacology. Thrombopoietin / pharmacology. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / genetics. Transfection. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11110686.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL-58707; United States / NHLBI NIH HHS / HL / R01 HL-61401; United States / NHLBI NIH HHS / HL / R01 HL-61849
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / CGS 27023A; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Chemotactic Factors; 0 / Culture Media, Serum-Free; 0 / Cxcl12 protein, mouse; 0 / Extracellular Matrix Proteins; 0 / Hydroxamic Acids; 0 / Matrix Metalloproteinase Inhibitors; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / Receptors, CXCR4; 0 / Recombinant Fusion Proteins; 0 / Sulfonamides; 0 / Tissue Inhibitor of Metalloproteinase-1; 9014-42-0 / Thrombopoietin; EC 3.4.21.5 / Thrombin; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


10. Savaşan S, Buck S, Raimondi SC, Becton DL, Weinstein H, Chang M, Ravindranath Y: CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome. Leuk Lymphoma; 2006 Oct;47(10):2076-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome.
  • The outcome for children with acute megakaryoblastic leukemia (AMKL) remains poor, except for cases associated with Down syndrome (DS).
  • This study compared immunophenotypic and drug sensitivity patterns of childhood AMKL cases with or without DS.
  • In children without DS, high expression of CD36 on AMKL blasts identified a sub-group with immunophenotypic and drug sensitivity patterns similar to that of DS AMKL.
  • CD36 expression in acute myeloid leukemia cases other than AMKL was not associated with increased in vitro drug sensitivity.
  • [MeSH-major] Antigens, CD36 / biosynthesis. Gene Expression Regulation, Neoplastic. Leukemia, Megakaryoblastic, Acute / complications. Leukemia, Megakaryoblastic, Acute / metabolism
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Cell Membrane / metabolism. Child. Child, Preschool. Cytarabine / pharmacology. Daunorubicin / pharmacology. Down Syndrome / complications. Humans. Immunophenotyping. Infant. Infant, Newborn. Sensitivity and Specificity. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Oct;47(10):2004-5 [17071466.001]
  • (PMID = 17071479.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / U10 CA 30969
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD36; 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


11. Mattei D, Mordini N, Lo Nigro C, Ghirardo D, Ferrua MT, Osenda M, Gallamini A, Bacigalupo A, Viscoli C: Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation. Bone Marrow Transplant; 2002 Dec;30(12):967-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.
  • A major problem is how to manage patients who had invasive aspergillosis during remission induction and consolidation therapy and then undergo SCT.
  • [MeSH-major] Aspergillosis / drug therapy. Bone Marrow Transplantation / adverse effects. Deoxycholic Acid / analogs & derivatives. Leukemia, Megakaryoblastic, Acute / therapy. Leukemia, Myelomonocytic, Acute / therapy. Lung Diseases, Fungal / drug therapy. Peripheral Blood Stem Cell Transplantation / adverse effects. Pyrimidines / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Adult. Amphotericin B / administration & dosage. Amphotericin B / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Drug Combinations. Drug Resistance, Fungal. Etoposide / administration & dosage. Etoposide / adverse effects. Fatal Outcome. Humans. Immunocompromised Host. Itraconazole / therapeutic use. Liposomes. Male. Middle Aged. Recurrence. Remission Induction. Salvage Therapy. Transplantation Conditioning / adverse effects. Transplantation, Autologous / adverse effects. Transplantation, Homologous / adverse effects. Voriconazole

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Aspergillosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • Hazardous Substances Data Bank. Itraconazole .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12476292.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Liposomes; 0 / Pyrimidines; 0 / Triazoles; 0 / liposomal amphotericin B; 005990WHZZ / Deoxycholic Acid; 04079A1RDZ / Cytarabine; 304NUG5GF4 / Itraconazole; 6PLQ3CP4P3 / Etoposide; 7XU7A7DROE / Amphotericin B; 87687-70-5 / amphotericin B, deoxycholate drug combination; JFU09I87TR / Voriconazole; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down






Advertisement